Skip to content
buyNotable cluster of 3

Ra Capital Management, L.p. bought $20M of EVMN

director, owner at Evommune, Inc.. 1,250,000 shares at an average of $16.00, traded Nov 7, 2025, filed Nov 12, 2025.

Conviction score
60
Value
$20M
1,250,000 shares
Holdings after
784,345
+82% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Director
    +15
  • Trade size
    $20.0M at market
    +25
  • Relative to holdings
    Holdings up 82%
    +10
  • Price context
    No price history yet
    0
  • Cluster
    3 insiders buying within 14 days
    +15
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Median 6-month excess return -38% over 3 past buys
    -5

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

EVMNOct 9, 2026 · close 6.25
Since filing Nov 12, 2025: -68.0%SPY +15.2% · excess -83.1%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001346824-25-000049, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Nov 7, 2025CConversion
Common Stockindirect: See Footnotes
+1,517,329--1,517,329Nov 12, 2025
Nov 7, 2025CConversion
Common Stockindirect: See Footnotes
+691,441--691,441Nov 12, 2025
Nov 7, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+1,157,096$16.00$19M2,674,425Nov 12, 2025
Nov 7, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+92,904$16.00$1.5M784,345Nov 12, 2025
Nov 7, 2025CConversion
Series C Preferred Stockderivativeindirect: See Footnotes
-12,924,620--0Nov 12, 2025
Nov 7, 2025CConversion
Series C Preferred Stockderivativeindirect: See Footnotes
-5,889,699--0Nov 12, 2025

Related signals

Other insiders at Evommune, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
23Weak
EVMNsell 210b5-1
Evommune, Inc.
David E Cohen
director
$123k
6,056 shares
-26%
16Weak
EVMNsell 210b5-1
Evommune, Inc.
Kyle Carver
Chief Financial Officer
$415k
18,175 shares
-23%
21Weak
EVMNbuy
Evommune, Inc.
Robert Lorne Hopfner
director, owner
$17k
1,000 shares
+33%
53Moderate
EVMNbuy 3
Evommune, Inc.
LSP 7 Cooperative UA
owner
$25M
1,562,500 shares
+46%
61Notable
EVMNbuy 3
Evommune, Inc.
Weegen Felice Isabel Verduyn-van
director, owner
$25M
1,562,500 shares
+46%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.